U.S. Healthtech Stock News

CAVA Group (CAVA) drew sharp investor attention after its fourth quarter earnings and 2026 outlook, which paired strong restaurant expansion plans with new menu items and a projected 3% to 5% increase in same restaurant sales. See our latest analysis for CAVA Group. Over the past year, CAVA Group has paired upbeat earnings headlines and expansion plans with sharp share price swings, including a 29.5% 30 day share price return and a 48.9% 90 day share price return. Its 1 year total shareholder...

In February 2026, Intuitive Machines, Inc. completed a private placement of 11,574,074 Class A shares at US$15.12 each, raising about US$175,000,000 from global institutional investors in a transaction exempt from Securities Act registration. The equity raise follows the largely cash-funded Lanteris acquisition and is intended to replenish the balance sheet while accelerating investment in Near Space Network Services, Lanteris satellite platforms, and a “solar system internet” spanning Earth...

Investors may be wondering whether Kroger, at around its recent US$69.05 close, is still a reasonable entry point or if most of the easy value is already on the table. The stock has returned 1.2% over the last 7 days, 9.9% over the past month, 9.7% year to date, 12.0% over 1 year, 58.7% over 3 years and 121.0% over 5 years. These returns may have shifted how the market views its risk and return trade off. Recent coverage has focused on Kroger's ongoing position as a major US grocery chain...

In recent months, Progressive reported higher net premiums written and earned, stronger underwriting margins with an improved combined ratio, and broad policy growth across personal, commercial, and property lines. An interesting angle is how its push into digital and direct-to-consumer channels appears to be amplifying this operational momentum across the entire franchise. Next, we’ll examine how this improved combined ratio and premium growth may influence Progressive’s existing investment...

Activist pressure puts ASA Gold and Precious Metals in focus Saba Capital Management LP has urged ASA Gold and Precious Metals (ASA) to conduct a comprehensive review, with an updated February 19 presentation outlining clarified alternatives for the Board to evaluate. For you as an investor, this kind of activist communication often raises questions around portfolio structure, capital allocation and potential changes that could affect how ASA trades relative to its underlying precious metals...

In February 2026, Kratos Defense & Security Solutions announced a US$12.40 million U.S. Air Force contract with GE Aerospace to complete preliminary design work on the GEK1500 next-generation 1,500‑lb thrust engine for small collaborative combat aircraft and unmanned systems, while Starfighters Space moved its STARLAUNCH 1 rocket program into Critical Design Review with GE Aerospace support. Together, these projects highlight GE Aerospace’s expanding role in affordable, high-performance...

Why Ouster’s latest earnings matter for investors Ouster (OUST) reported fourth quarter revenue of US$62.18 million and net income of US$3.99 million, compared with US$30.09 million revenue and a net loss of US$23.74 million a year earlier. Basic earnings per share from continuing operations came in at US$0.07, with diluted EPS at US$0.06, versus a basic and diluted loss of US$0.48 per share in the prior year period. See our latest analysis for Ouster. The earnings beat and the recently...

If you are wondering whether MetLife’s current share price reflects its true worth, this article explains how the market might be pricing the stock today. MetLife last closed at US$73.24, with returns of a 2.7% decline over 7 days, a 7.2% decline over 30 days, an 8.8% decline year to date, and a 12.0% decline over 1 year, compared with gains of 15.3% over 3 years and 41.2% over 5 years. These mixed returns sit against a backdrop of ongoing news coverage around the company’s position as a...

D-Wave Quantum (QBTS) has drawn fresh attention as investors reassess this US quantum computing provider after recent share price swings and a mixed return profile, including a 1-day gain alongside weaker performance over the past month and past 3 months. See our latest analysis for D-Wave Quantum. At the current share price of $18.94, D-Wave Quantum shows a 7-day share price return of 4.93% and a 90-day share price return of 15.82%. The 1-year total shareholder return remains very large,...

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation. Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...

Roku (ROKU) just followed up a stronger fourth quarter with a slot at Bernstein’s “What’s next in tech?” forum, giving investors fresh context on its earnings, platform reach, and position as a neutral streaming aggregator. See our latest analysis for Roku. Roku’s recent 16.2% 7 day share price return and 22.2% 1 year total shareholder return sit against a weaker year to date share price return of 9.8% decline, suggesting momentum has picked up again around its earnings and platform...

Nuvation Bio (NUVB) just finalized a protocol amendment that advances its global SIGMA safusidenib study into Phase 3, widening access for high risk IDH1 mutant astrocytoma patients and drawing additional investor attention to upcoming earnings. See our latest analysis for Nuvation Bio. The share price, now at US$5.84, has a 7 day share price return of 7% and a 30 day share price return of 11%, but a 90 day share price return of a 22% decline. The 1 year total shareholder return is over 3x...

UroGen Pharma FY 2025 results set the stage for growth versus losses debate UroGen Pharma (URGN) closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.54, alongside a trailing twelve month loss of US$3.19 per share on US$109.8 million of revenue. The company has seen quarterly revenue move from US$24.6 million in Q4 2024 to US$37.8 million in Q4 2025. Over the same period, basic EPS ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.54 in the latest...

Why KLA (KLAC) is on investors’ radar right now KLA (KLAC) has drawn fresh attention after its recent share move, with the stock last closing at US$1,534.95 and delivering a 7.5% return over the past month and 29% in the past 3 months. See our latest analysis for KLA. Beyond the recent move, KLA’s momentum has been building, with a 7 day share price return of 3.2%, a 30 day return of 7.5% and a 1 year total shareholder return of about 124%, pointing to strong recent enthusiasm for the...

Interactive Brokers Group (NasdaqGS:IBKR) reports strong growth in client activity and trading volumes. The broker launches stablecoin funding for U.S. clients, allowing deposits in certain digital dollar tokens. The company highlights continued progress in brokerage technology and its inclusion in the S&P 500 Index. Interactive Brokers Group, trading at around $71.67, sits in a very different place than it did a few years ago, with a 1 year return of 43.0% and a 5 year return of 288.5%...

Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans. A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial. We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...

In February 2026, UMH Properties, Inc. reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$66.97 million but quarterly net income slipping to US$4.64 million, while full-year revenue climbed to US$261.75 million and net income to US$26.5 million. Alongside these mixed quarterly figures, UMH outlined plans for continued portfolio expansion and issued upbeat 2026 guidance, highlighting expectations for higher normalized FFO and earnings per share...

If you are wondering whether Bunge Global’s current share price lines up with its underlying worth, this article walks through the key numbers that matter for valuation. The stock recently closed at US$120.61, after a 0.6% decline over 7 days, a 5.9% gain over 30 days, and returns of 30.2% year to date, 73.1% over 1 year, 34.3% over 3 years, and 75.8% over 5 years. Recent coverage has focused on Bunge Global’s role in global agribusiness and food supply chains and how that positioning may...

Why Fresh Del Monte Produce (FDP) is back in focus Fresh Del Monte Produce (FDP) just reported fourth quarter and full year 2025 results, along with a fresh dividend declaration and an update on its completed share buyback. This gives investors several moving parts to assess at once. See our latest analysis for Fresh Del Monte Produce. The recent update on earnings, dividends and buybacks comes after a strong run in the share price, with a 16.84% 3 month share price return and a 47.18% 1 year...

NextEra Energy (NEE) has just completed a $2 billion composite units offering, combining future common stock purchase contracts with debentures, to fund energy and power projects and broader corporate needs, including debt repayment. See our latest analysis for NextEra Energy. At a share price of $92.71, NextEra Energy has seen a 30 day share price return of 5.47% and a 90 day share price return of 9.61%. Its 1 year total shareholder return of 33.29% and 5 year total shareholder return of...

Cullen/Frost Bankers (CFR) has drawn fresh attention after recent trading, with the share price closing at $140.21 and posting mixed short term returns while still showing gains over the past 3 months and year. See our latest analysis for Cullen/Frost Bankers. The recent 1 day share price return of 1.44% sits against a 7 day share price return of negative 1.35%. At the same time, the 90 day share price return of 13.93% and 1 year total shareholder return of 7.14% point to momentum that has...

Apogee Therapeutics reported a full-year net loss of US$255.84 million for 2025, with basic and diluted loss per share of US$4.22 as it continued to report no product revenue while investing heavily in its antibody pipeline. Alongside deeper losses, the company underscored upcoming clinical milestones for zumilokibart and other programs and filed a US$287.29 million shelf registration tied to an employee stock ownership plan, highlighting both capital needs and efforts to align employee...

Astera Labs has recently deepened its AI data center role by acquiring aiXscale Photonics, expanding with an Israel Design Center, and advancing its vendor‑neutral connectivity solutions through UALink participation and hyperscaler partnerships. This expansion into optical interconnects and closer collaboration with major cloud providers could reinforce Astera Labs’ position as a key infrastructure enabler in next‑generation AI data centers. We’ll now examine how the aiXscale Photonics...

ImmunityBio (IBRX) is back in focus after completing enrollment ahead of schedule in its Phase 2 ANKTIVA bladder cancer trial. Interim data show statistically significant response durability compared with BCG alone and no significant safety concerns. See our latest analysis for ImmunityBio. The latest ANKTIVA trial update arrives after a significant 3-month share price return of about 3.7x and a 416.83% year-to-date share price return, alongside a 245.70% 1-year total shareholder return. This...